Testicular Tissue Cryopreservation for Fertility Preservation
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- University of Pittsburgh
- Study ID
- NCT02972801
- Status
- Recruiting
Conditions
- Autoimmune Disorders
- Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Testicular biopsy — PROCEDURETesticular biopsy is performed to obtain testicular tissue for cryopreservation
Study Details
Testicular tissue cryopreservation is an experimental procedure where a young boy's testicular tissue is retrieved and frozen. This technique is reserved for young male patients who are not yet producing mature sperm, with the ultimate goal that their tissue may be used in the future to restore fertility when experimental techniques emerge from the research pipeline.
Key Dates
- Start date
- Jan 6, 2010
- Status verified
- Apr 2026
- Primary completion
- Dec 28, 2029
- Completion
- May 31, 2030
Study Design
- Enrollment
- 1,500 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Testicular tissue biopsyTesticular biopsy
Primary Outcome Measure
Presence of spermatogonial stem cells in the testicular tissue as determined by histology. [ Time Frame: 5 years ]
Central Contacts
- Jen Anglin412-641-7475
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Magee-Womens Hospital | Pittsburgh | Pennsylvania | 15213 |
Find similar trials in Pittsburgh, PA
By research site
Related Studies
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer PatientsRecruiting · Thomas Jefferson University · Philadelphia, Pennsylvania
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsPHASE1/PHASE2 · Recruiting · Immatics US, Inc. · Stanford, California